CoChat

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Open access
Finn, Stephen P., Addeo, Alfredo, Dafni, Urania, Thunnissen, Erik, Bubendorf, Lukas, Madsen, Line Bille, Biernat, Wojciech, Verbeken, Eric, Hernandez-Losa, Javier, Marchetti, Antonio, Cheney, Richard, Warth, Arne, Speel, Ernst-Jan M., Quinn, Anne Marie, Monkhorst, Kim, Jantus-Lewintre, Eloisa, Tischler, Verena, Marti, Nesa, Dimopoulou, Georgia, Molina-Vila, Miguel A., Kammler, Roswitha, Kerr, Keith M., Peters, Solange, Stahel, Rolf A. · 2021 · Journal of Thoracic Oncology
Cited by 63

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

INTRODUCTION KRAS mutations, the most frequent gain-of-function alterations in non-small cell lung cancer (NSCLC), are currently emerging as potential predictive therapeutic targets. KRAS-G12C (Kr_G12C) role is of special interest, following the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). METHODS KRAS mutations were assessed in FFPE tissue sections by a microfluidics-based multiplex PCR platform as a component of the previously published ETOP Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I-III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathological characteristics, molecular profiles and post-operative patient outcome (Overall Survival (OS), Relapse-free Survival (RFS), Time-to-Relapse (TTR)) was explored. RESULTS KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 (49%)) with I/II/III stage distribution: 53%/24%/22%, and median follow-up: 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0%;95%CI:35.0%-41.0%, with Kr_G12C mutation representing 17.0%;95%CI:14.7%-19.4%. In the "all-histologies" cohort, Kr_G12C prevalence was 10.5%;95%CI:9.2%-11.9%. When adjusting for clinicopathological characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or non-existence of KRAS mutation was identified in the adenocarcinoma cohort alone and also in the 'all-histology' cohort. For OS in adenocarcinomas: HRG12C_vs_other_KRAS=1.39;95%CI:1.03-1.89;p=0.031 and HRG12C_vs_noKRAS=1.32;95%CI:1.03-1.69;p=0.028 (both also significant in the "all-histologies" cohort) while for TTR: HRG12C_vs_other_KRAS=1.41;95%CI:1.03-1.92;p-value=0.030. Also, among all patients, for RFS: HRG12C_vs_noKRAS=1.27;95%CI:1.04-1.54;p=0.017. CONCLUSION In this large, clinically annotated stage I-III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathological characteristics) among adenocarcinomas as well as in unselected NSCLCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2021.02.016

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 63

Metadata

Authors
Finn, S. P., Addeo, A., Dafni, U., Thunnissen, E., Bubendorf, L., Madsen, L. B., Biernat, W., Verbeken, E., Hernandez-Losa, J., Marchetti, A., Cheney, R., Warth, A., Speel, E.-J. M., Quinn, A. M., Monkhorst, K., Jantus-Lewintre, E., Tischler, V., Marti, N., Dimopoulou, G., Molina-Vila, M. A., Kammler, R., Kerr, K. M., Peters, S., & Stahel, R. A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-06
Volume
16
Issue
6
Pages
990-1002
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3134146062
Cited by
63
References
9
FWCI
6.52
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.